Terns Pharmaceuticals (TERN) News Today $4.01 +0.13 (+3.35%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$4.20 +0.19 (+4.61%) As of 06/16/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TERN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Insider Buying: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Buys 5,000 Shares of StockTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Andrew Gengos purchased 5,000 shares of the company's stock in a transaction dated Monday, June 16th. The shares were acquired at an average price of $3.95 per share, for a total transaction of $19,750.00. Following the purchase, the chief financial officer now directly owns 15,000 shares of the company's stock, valued at approximately $59,250. The trade was a 50.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.June 16 at 9:08 PM | marketbeat.comAndrew Gengos Buys 10,000 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Andrew Gengos purchased 10,000 shares of the stock in a transaction that occurred on Friday, June 13th. The shares were bought at an average cost of $3.73 per share, for a total transaction of $37,300.00. Following the acquisition, the chief financial officer now owns 10,000 shares of the company's stock, valued at approximately $37,300. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.June 16 at 9:08 PM | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) have received an average rating of "Moderate Buy" from the five brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and three havJune 14 at 3:44 AM | marketbeat.comNASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies | DelveInsightJune 13, 2025 | theglobeandmail.com3 Penny Stocks Wall Street Sees With 243% UpsideJune 11, 2025 | 247wallst.comBank of America Corp DE Purchases 138,661 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Bank of America Corp DE lifted its stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 236.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 197,226 shares of the company's stock after acquiring aJune 7, 2025 | marketbeat.comVoloridge Investment Management LLC Sells 98,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Voloridge Investment Management LLC lowered its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 62.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor oMay 31, 2025 | marketbeat.comTerns Pharmaceuticals to Participate in Upcoming June Investor ConferencesMay 29, 2025 | globenewswire.comInfinitum Asset Management LLC Takes $1.11 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Infinitum Asset Management LLC acquired a new position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 200,000 shares of the company's stock, valued at approximately $1,108,000.May 28, 2025 | marketbeat.comTerns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potentialMay 27, 2025 | investing.comNuveen Asset Management LLC Buys 617,009 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Nuveen Asset Management LLC grew its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 30.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,633,918 shares of the company's stMay 27, 2025 | marketbeat.comNorthern Trust Corp Has $3.28 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Northern Trust Corp increased its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 27.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 591,171 shares of the company's stock after purchasing anMay 26, 2025 | marketbeat.comDeutsche Bank AG Has $2.21 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Deutsche Bank AG lessened its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 26.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 398,379 shares of the company's stockMay 25, 2025 | marketbeat.comVR Adviser LLC Sells 2,332,968 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)VR Adviser LLC trimmed its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 68.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,077,090 shares of the company's stock after selling 2,332,96May 22, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Position Cut by Point72 Asset Management L.P.Point72 Asset Management L.P. trimmed its stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 53.8% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,251,841 shares of the company's stock after selling 1,455,674 shares during the quartMay 22, 2025 | marketbeat.comCubist Systematic Strategies LLC Decreases Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Cubist Systematic Strategies LLC decreased its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 93.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,964 shares of the company's stock after selliMay 22, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires New Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)BNP Paribas Financial Markets purchased a new position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 224,265 shares of the company's stock, valuedMay 22, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) is Soleus Capital Management L.P.'s 10th Largest PositionSoleus Capital Management L.P. raised its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 30.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,142,500 shares of the company's stock after purchasing an additional 1,918,95May 21, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Graham Capital Management L.P.Graham Capital Management L.P. lifted its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 897.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 132,999 shares of the company's stock after purchMay 17, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC boosted its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 51.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 829,105 shares of the company's stock afterMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 192.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 140,May 16, 2025 | marketbeat.comTerns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701May 14, 2025 | globenewswire.comTerns Pharmaceuticals (NASDAQ:TERN) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPSTerns Pharmaceuticals (NASDAQ:TERN - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.03.May 14, 2025 | marketbeat.comIntegral Health Asset Management LLC Increases Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Integral Health Asset Management LLC increased its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 50.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 450,000 shares of the compaMay 14, 2025 | marketbeat.comDimensional Fund Advisors LP Raises Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Dimensional Fund Advisors LP boosted its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 107.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,302,932 shares of the company's stock after purchasing an additionaMay 13, 2025 | marketbeat.comDriehaus Capital Management LLC Decreases Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Driehaus Capital Management LLC lessened its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 20.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,661,846 shares of the coMay 12, 2025 | marketbeat.comIs Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | insidermonkey.comTerns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 8, 2025 | globenewswire.comTerns Pharmaceuticals (TERN) to Post Earnings on MondayTerns Pharmaceuticals (NASDAQ:TERN) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-terns-pharmaceuticals-inc-stock/)May 7, 2025 | marketbeat.comJPMorgan Chase & Co. Reduces Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)JPMorgan Chase & Co. cut its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 70.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 51,830 shares of the company's stock after selling 123,506 shares during the quMay 5, 2025 | marketbeat.comAcorn Capital Advisors LLC Invests $10.92 Million in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Acorn Capital Advisors LLC bought a new stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 1,971,264 shares of the company's stock, valued at approximately $10,921,000. Terns PharmaceutMay 4, 2025 | marketbeat.comBoxer Capital Management LLC Takes $4.17 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Boxer Capital Management LLC acquired a new stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 752,000 shares of the company'sMay 4, 2025 | marketbeat.comTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)May 2, 2025 | globenewswire.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Acquired by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC grew its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 44.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,751,506 sharesMay 1, 2025 | marketbeat.comTerns Pharmaceuticals to Participate in The Citizens Life Sciences ConferenceApril 30, 2025 | globenewswire.comBarclays PLC Purchases 575,069 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Barclays PLC grew its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 444.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 704,371 shares of the company's stock after purchasing an additional 575,069 shares duriApril 29, 2025 | marketbeat.comMarshall Wace LLP Grows Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Marshall Wace LLP boosted its stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 666.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 803,336 shares of the company's stock after buyiApril 27, 2025 | marketbeat.comGeode Capital Management LLC Has $8.40 Million Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Geode Capital Management LLC boosted its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 25.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,516,478 shares of the company's stock afteApril 26, 2025 | marketbeat.comRenaissance Technologies LLC Grows Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Renaissance Technologies LLC grew its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 30.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 623,134 shares of the company's stock aApril 25, 2025 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Given Market Outperform Rating at JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $20.00 target price on shares of Terns Pharmaceuticals in a report on Monday.April 23, 2025 | marketbeat.comDoes Terns Pharmaceuticals Have A Long Cash Runway?April 23, 2025 | finance.yahoo.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Altium Capital Management LLCAltium Capital Management LLC grew its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 43.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 475,000 shares of the company's stock after purchasApril 20, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock Position Raised by LPL Financial LLCLPL Financial LLC raised its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 397.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 252,325 shares oApril 20, 2025 | marketbeat.comRussell Investments Group Ltd. Decreases Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Russell Investments Group Ltd. decreased its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 15.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 628,395 shares ofApril 19, 2025 | marketbeat.comAlliancebernstein L.P. Has $2.01 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Alliancebernstein L.P. lifted its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 48.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 362,359 shares of the company's stocApril 19, 2025 | marketbeat.comVanguard Group Inc. Has $21.44 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Vanguard Group Inc. lifted its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 15.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,869,582 shares of the compApril 17, 2025 | marketbeat.comExodusPoint Capital Management LP Lowers Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)ExodusPoint Capital Management LP lowered its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 99.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,816April 16, 2025 | marketbeat.comNorges Bank Acquires New Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Norges Bank purchased a new position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 849,389 shares of the company's stock, valued at approximately $4,706,000April 12, 2025 | marketbeat.comPolymer Capital Management HK LTD Increases Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Polymer Capital Management HK LTD increased its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 637.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 177,000 shares of the companApril 9, 2025 | marketbeat.comTerns Pharmaceuticals management to meet with OppenheimerApril 8, 2025 | markets.businessinsider.com Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address TERN Media Mentions By Week TERN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TERN News Sentiment▼1.260.90▲Average Medical News Sentiment TERN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TERN Articles This Week▼84▲TERN Articles Average Week Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qilian International Holding Group News Today Amphastar Pharmaceuticals News Today Calliditas Therapeutics AB (publ) News Today Structure Therapeutics News Today Aurinia Pharmaceuticals News Today Wave Life Sciences News Today Niagen Bioscience News Today Mineralys Therapeutics News Today Arcus Biosciences News Today Spyre Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TERN) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
